Research programme: therapeutic monoclonal antibodies - Takeda/XOMA

Drug Profile

Research programme: therapeutic monoclonal antibodies - Takeda/XOMA

Latest Information Update: 04 Nov 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Takeda; XOMA
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Cancer; Unspecified

Most Recent Events

  • 01 Nov 2010 XOMA receives grant under The Patient Protection and Affordable Care Act of 2010 (PPACA) for therapeutic monoclonal antibody development in Cancer
  • 15 Apr 2010 XOMA receive $US1 million milestone payment from Takeda
  • 10 Feb 2009 XOMA and Takeda expand their collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top